Research Article
Weight Loss Induced by Bariatric Surgery Restricts Hepatic GDF15 Expression
Table 1
Clinical characteristics of patients before and after LAGB.
| | Before LAGB | After LAGB | value |
| | N (female/male) | 28 (21/7) | — | — | | Age | 38 [19–66] | — | — | | BMI (kg/m2) | 43.01 ± 3.70 | 35.7 ± 4.53 | | | Weight loss (kg) | 21.90 ± 9.76 | — | — | | % excessive weight loss | 39.57 ± 17.92 | — | — | | Fasting glucose (mg/dl) | 103.02±17.81 | 89.47 ± 9.17 | | | Insulin (U/I) | 20.85 ± 15.06 | 11.89 ± 7.87 | | | HOMA | 5.53 ± 4.54 | 2.71 ± 2.05 | | | AST (U/L) | 30.59 ± 12.93 | 25.44 ± 7.14 | | | ALT (U/L) | 36.45 ± 27.90 | 23.89 ± 12.30 | | | GGT (U/L) | 36.04 ± 24.57 | 25.64 ± 16.41 | | | AP (U/L) | 66.86 ± 17.87 | 66.00 ± 11.37 | | | CRP (mg/dl) | 1.01 ± 0.73 | 0.63 ± 0.35 | | | Leukocyte count (G/L) | 7.32 ± 1.88 | 6.48 ± 1.39 | |
|
|
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; HOMA, homeostasis model assessment (calculated as Insulin (µU/ml) × glucose (mmol/l)/22.5); GGT, γ-glutamyl transferase.
|
